Compare Charles River Laboratories Intl. Inc (CRL) vs iShares MSCI France ETF (EWQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs iShares MSCI France ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $228.01 (market cap $11.14B), while iShares MSCI France ETF trades at $45.26. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, iShares MSCI France ETF nearer its low. Which is the better fit depends on your goals.
| CRL | EWQ | |
|---|---|---|
Market Cap | $11.14B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $233.60 | $48.35 |
52-Week Low | $145.57 | $41.43 |
Enterprise Value | $14.00B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
EWQ is currently trading at $44.83, down 0.47% on the day, with technical indicators showing a bearish trend as moving averages signal strong selling pressure. The stock faces resistance at $45 and support at $44, with oscillators remaining neutral. Recent corporate actions include a $1.09 dividend scheduled for payment in June 2026, providing income potential for long-term holders.
The outlook remains cautious due to technical weakness and European market volatility from ECB rate hikes and energy price pressures. Investment opportunity exists through dividend income, but risks include geopolitical tensions affecting European equities and potential short-squeeze volatility. The stock requires careful monitoring of European economic developments and technical breakout levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About iShares MSCI France ETF
EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.
Read more on EWQ →
